On 29 January 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.
Since the announcement as of 4 May 2009, the following transactions have been made under the programme:
|
|
Number of
shares |
Average purchase
price |
Transaction
value, DKK |
|
Accumulated, last
announcement |
5,267,641 |
|
1,453,764,425 |
|
4 May 2009 |
90,000 |
274.18 |
24,676,200 |
|
5 May 2009 |
90,000 |
274.08 |
24,667,200 |
|
6 May 2009 |
85,000 |
274.02 |
23,291,700 |
|
7 May 2009 |
159,541 |
267.84 |
42,731,461 |
|
Accumulated under
the programme |
5,692,182 |
|
1,569,130,987 |
Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 4,109 B shares in the period from 4 May to 7 May. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 30,510,025 treasury shares, corresponding to 4.8% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.
The Annual General Meeting of Novo Nordisk A/S, which was held on 18 March 2009, approved a 2.2% reduction in the total share capital by cancellation of 14,000,000 treasury B shares of DKK 1 at a nominal value of DKK 14,000,000. After the legal implementation of the share capital reduction, which is expected to take place after expiry of the legal notice period in June 2009, Novo Nordisk's share capital will amount to DKK 620,000,000 divided into an A share capital of DKK 107,487,200 and a B share capital of DKK 512,512,800. Taking into account the expected cancellation Novo Nordisk would currently own 2.7% of such reduced share capital.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Further information:
|
Media: |
Investors: |
|
|
|
|
Outside North America: |
Outside North America: |
|
Elin K Hansen |
Mads Veggerby Lausten |
|
Tel: (+45) 4442 3450 |
Tel: (+45) 4443 7919 |
|
|
|
|
|
Kasper Roseeuw Poulsen |
|
|
Tel: 4442 4471 |
|
|
|
|
|
|
|
In North America: |
In North America: |
|
Sean Clements |
Hans Rommer |
|
Tel: (+1) 609 514 8316 |
Tel: (+1) 609 919 7937 |
Company Announcement no 27 / 2009
